Market Place
Sourcing Support
Hengkang Pharma invites global customers to join CPHI exhibition
08 Oct 2024 //
PRESS RELEASE
Lupin launches Mirabegron Extended-Release Tablets in the US
04 Sep 2024 //
EXPRESSPHARMA
Zydus launches Mirabegron Extended-Release Tablets in the US
22 Apr 2024 //
BUSINESSWIRE
Astellas’ generic Myrbetriq defence knocked back again
20 Apr 2024 //
PHARMAPHORUM
Alkem Lab`s Generic Mirabegro Receives Approval in the U.S.
12 Feb 2024 //
FDA
Astellas loses patent infringement case over blockbuster bladder drug
14 Jun 2023 //
ENDPTS
Alkem`s Generic Mirabegron Receives Approval in the U.S.
09 Jan 2023 //
FDA
Lupin`s Generic Mirabegron Receives Approval in the U.S.
28 Sep 2022 //
FDA
FDA Approves New indication for Drug to Treat Neurogenic Detrusor
26 Mar 2021 //
FDA
FDA Accepts for Priority Review the New Drug Application for mirabegron
06 Jan 2021 //
PRNEWSWIRE
As Urovant preps vibegron launch, it’s all systems go on R&D
15 Aug 2020 //
FIERCE PHARMA
Sawai USA Generic Mirabegron Receives Approval in US
27 Dec 2019 //
FDA
Union Quimico Farmaceutica Fails EDQM Inspection
29 Oct 2019 //
EDQM
Lupin Ltd.`s Generic Mirabegron Receives Tentative Approval In US
26 Jun 2019 //
FDA
Zydus Pharms USA`s Generic Mirabegron Receives Tentative Approval in US
03 Apr 2019 //
FDA
Cadila Healthcare gains on USFDA`s tentative approval to market a drug
02 Apr 2019 //
MONEYCONTROL
Urovant claims a big win in PhIII — but questions linger about a cheap generic
18 Mar 2019 //
ENDPTS
Aurobindo Pharma`s Generic Mirabegron Receives Tentative Approval in US
16 Oct 2018 //
FDA
Overactive bladder biotech Urovant Sciences sets terms for $150 million IPO
17 Sep 2018 //
NASDAQ
Astellas Announces Launch of "What`s Next Sweepstakes" with Laila Ali
12 Sep 2018 //
PR NEWSWIRE
Urovant seeks $150M IPO just a year after launch
16 Jul 2018 //
FIERCE BIOTECH
FDA Approves Supplemental NDA for Myrbetriq® (mirabegron)
07 May 2018 //
PR NEWSWIRE
Urovant starts pursuit of Astellas’ incontinence drug Myrbetriq
28 Mar 2018 //
FIERCE BIOTECH
U.S. FDA Accepts for Review Astellas` Supplemental NDA for mirabegron
12 Sep 2017 //
PR NEWSWIRE
Astellas goes `Dancing with the Stars` for new Myrbetriq promo
11 Sep 2017 //
FIERCE PHARMA
Astellas Submits Supplemental NDA for Mirabegron for Use in Combination
29 Jun 2017 //
PR NEWSWIRE
Astellas and Gedeon named for ABPI Code breaches
08 Jun 2017 //
PHARMA TIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.